Tadashi Watabe

Osaka University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (3)

Yoshifumi Shirakami

Specially Appointed Associate Professor

Osaka University

JAPAN

View details

Hiroyuki Suzuki

Chiba University

JAPAN

View details

Koichi Fukase

Professor

Osaka University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tadashi Watabe

Research Interests

Explore related searches

Contact this professor

Articles (10)

An 211At-labeled alpha-melanocyte stimulating hormone peptide analog for targeted alpha therapy of metastatic melanoma

Development of PSMA-Targeted Alpha Therapy Using [211At]PSMA-5

Recent advances in theranostics and oncology PET: emerging radionuclides and targets

Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part II: low-grade group

Theranostics using 89Zr/177Lu-labeled antibody targeting erythropoietin-producing hepatocellular A2 (EphA2)

First-in-human SPECT/CT imaging of [211At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer

Preclinical Evaluation of Biodistribution and Toxicity of [<sup>211</sup>At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211

Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target

Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models

Collaborators (3)

Yoshifumi Shirakami

Hiroyuki Suzuki

Koichi Fukase

Make your next move.